

Carla Iacobini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2747756/publications.pdf>

Version: 2024-02-01

33
papers

1,897
citations

257450

24
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

3176
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2). <i>Diabetes Care</i> , 2022, 45, 213-221.	8.6	15
2	Food-Related Carbonyl Stress in Cardiometabolic and Cancer Risk Linked to Unhealthy Modern Diet. <i>Nutrients</i> , 2022, 14, 1061.	4.1	13
3	Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future. <i>Antioxidants</i> , 2021, 10, 727.	5.1	60
4	Normalizing HIF-1 α Signaling Improves Cellular Glucose Metabolism and Blocks the Pathological Pathways of Hyperglycemic Damage. <i>Biomedicines</i> , 2021, 9, 1139.	3.2	12
5	Diabetes and Pancreatic Cancer—A Dangerous Liaison Relying on Carbonyl Stress. <i>Cancers</i> , 2021, 13, 313.	3.7	35
6	The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders. <i>Cells</i> , 2020, 9, 1812.	4.1	47
7	Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in KrasG12D/+ mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 152.	8.6	15
8	Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. <i>Scientific Reports</i> , 2020, 10, 20070.	3.3	6
9	L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes. <i>Current Medicinal Chemistry</i> , 2020, 27, 1744-1763.	2.4	26
10	Metabolically healthy versus metabolically unhealthy obesity. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 51-60.	3.4	251
11	Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 149-158.	3.4	27
12	The advanced glycation end-product N ^ε -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. <i>Journal of Pathology</i> , 2018, 245, 197-208.	4.5	43
13	Dietary interventions to contrast the onset and progression of diabetic nephropathy: A critical survey of new data. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1671-1680.	10.3	7
14	FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice. <i>British Journal of Pharmacology</i> , 2018, 175, 53-66.	5.4	32
15	Role of Galectin-3 in Bone Cell Differentiation, Bone Pathophysiology and Vascular Osteogenesis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2481.	4.1	31
16	Deficiency of the Purinergic Receptor 2X ₇ Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-14.	4.0	23
17	Correlates of Calcaneal Quantitative Ultrasound Parameters in Patients with Diabetes: The Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-12.	2.3	7
18	Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-7.	4.0	61

#	ARTICLE	IF	CITATIONS
19	A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies. <i>Annals of Anatomy</i> , 2016, 207, 2-8.	1.9	12
20	Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study (IDES). <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 355-363.	2.8	31
21	Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in ApoE-null mice. <i>Diabetologia</i> , 2015, 58, 845-853.	6.3	59
22	The dark and bright side of atherosclerotic calcification. <i>Atherosclerosis</i> , 2015, 238, 220-230.	0.8	147
23	Galectin-3: an emerging all-out player in metabolic disorders and their complications. <i>Glycobiology</i> , 2015, 25, 136-150.	2.5	94
24	The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. <i>Cardiovascular Research</i> , 2013, 100, 472-480.	3.8	106
25	The purinergic 2X₇ receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. <i>Journal of Pathology</i> , 2013, 231, 342-353.	4.5	99
26	Dâ€carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. <i>British Journal of Pharmacology</i> , 2012, 166, 1344-1356.	5.4	72
27	Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver. <i>Journal of Hepatology</i> , 2011, 54, 975-983.	3.7	127
28	Accelerated Lipid-Induced Atherogenesis in Galectin-3-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 831-836.	2.4	85
29	Advanced lipoxidation endâ€products mediate lipidâ€induced glomerular injury: role of receptorâ€mediated mechanisms. <i>Journal of Pathology</i> , 2009, 218, 360-369.	4.5	64
30	Galectinâ€3/AGEâ€receptor 3 knockout mice show accelerated AGEâ€induced glomerular injury: evidence for a protective role of galectinâ€3 as an AGE receptor. <i>FASEB Journal</i> , 2004, 18, 1773-1775.	0.5	93
31	Role of Galectin-3 in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S264-S270.	6.1	84
32	Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non-enzymatic glycation and polyol pathway activation. <i>Diabetes/Metabolism Research and Reviews</i> , 2001, 17, 448-458.	4.0	25
33	Role of galectin-3 as a receptor for advanced glycosylation end products. <i>Kidney International</i> , 2000, 58, S31-S39.	5.2	88